Xenetic Biosciences (STU:3XB0) Defensive Interval Ratio

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:3XB0 Xenetic Biosciences Inc STU:3XB0
81 GF Score
Price €3.10
GF Value €2.52
! 2 Warning Signs
View Full Analysis

What is Xenetic Biosciences Defensive Interval Ratio?

STU:3XB0
81GF Score
Xenetic Biosciences Inc STU:3XB0
Defensive Interval Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Xenetic Biosciences (STU:3XB0) Overvalued in 2026?

Based on GuruFocus' analysis, Xenetic Biosciences stock appears to be overvalued. The current stock price of €3.10 is trading 23% above its estimated GF Value™ of €2.52.

Key valuation signals for STU:3XB0:

  • Defensive Interval Ratio:
  • GF Value™: €2.52 vs. price of €3.10 (23% above fair value)
  • GF Score™: 81/100 with 2 warning signs

No single metric tells the full story. See the STU:3XB0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Xenetic Biosciences Business Description

Other Exchanges XBIO:USA
Address 945 Concord Street, Framingham, MA, USA, 01701
Xenetic Biosciences Inc is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas. XCART has the potential to fuel a robust pipeline of therapeutic assets targeting high-value oncology indications. Additionally, Xenetic is leveraging PolyXen™, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. PolyXen™ has demonstrated its ability to improve the half-life and other pharmacological properties of next-generation biologic drugs. The Company has an exclusive license agreement with Takeda Pharmaceuticals Co. Ltd. in the field of coagulation disorders and expects to earn royalty payments under this agreement.
81GF Score

Get the complete analysis for STU:3XB0

Defensive Interval Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.10
Price
€2.52
GF Value